Relay Therapeutics Q4 2023 GAAP EPS $(0.67) Beats $(0.75) Estimate
Portfolio Pulse from Benzinga Newsdesk
Relay Therapeutics reported a Q4 2023 GAAP EPS of $(0.67), surpassing the analyst consensus estimate of $(0.75) by 10.67%.
February 22, 2024 | 9:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relay Therapeutics reported a Q4 2023 GAAP EPS of $(0.67), outperforming the consensus estimate of $(0.75) by 10.67%.
Beating the consensus EPS estimate typically indicates better-than-expected financial health and operational efficiency, which can lead to positive investor sentiment and potentially increase the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100